T1	Participants 0 85	Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus
T2	Participants 108 168	acid has been recommended as a first-line hypolipidemic drug
T3	Participants 290 346	13 patients were treated in a randomized crossover trial
T4	Participants 170 288	To determine the effectiveness of nicotinic acid in dyslipidemic patients with non-insulin-dependent diabetes mellitus
T5	Participants 348 462	Patients received either nicotinic acid (1.5 g three times daily) or no therapy (control period) for 8 weeks each.
T6	Participants 795 899	nicotinic acid therapy resulted in the deterioration of glycemic control, as evidenced by a 16% increase
T7	Participants 939 1044	a 21% increase in glycosylated hemoglobin levels, and the induction of marked glycosuria in some patients
T8	Participants 1059 1120	a consistent increase in plasma uric acid levels was observed
T9	Participants 1400 1512	the drug not be used as a first-line hypolipidemic drug in patients with non-insulin-dependent diabetes mellitus
